| Literature DB >> 31288094 |
Rosemarie de la Cruz Bernabe1, Ghislaine J M W van Thiel2, Nancy S Breekveldt3, Christine C Gispen3, Johannes J M van Delden2.
Abstract
Although EU inspectors and clinical assessors are mandated to identify and act upon ethical issues, regulators lack guidance on how this can be done. Hence, we propose a four-step regulatory approach on ethically relevant GCP violation findings. The first step is identification of the ethical issue. Next is analysis [i.e., identifying the gravity (intensity or severity) and the magnitude (amount and duration) of the ethics violation as well as the responsible person(s) or entity or entities]. The third step is evaluation, (i.e., the process of deliberating to determine the significance of the ethics violation, with the intention of identifying the most reasonable sanction and/or corrective or reparative action). Last is decision-making or the process of choosing and implementing a regulatory course of action.Entities:
Mesh:
Year: 2019 PMID: 31288094 DOI: 10.1016/j.drudis.2019.07.001
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851